A major step forward in the controversial practice of stem cell research occurred today as the FDA approved a leading bio tech company, Geron Crop, to conduct experiments on up to 10 patients with spinal cord injuries. The historic decision marks a reversal of ethics-driven policy restricting the study and medical application of embryonic stem cells; critics complain it destroys human life. Its proponents, however, look forward to capitalizing on the untapped potential of stem cells to regenerate vital tissue and organs: "This is the dawn of a new era in medical therapeutics," said the CEO of Geron. He stressed that the medical benefit of the practice "goes beyond what pills and scalpels can ever do."
Read it at The Wall Street Journal
